Difference between revisions of "Antiphospholipid antibody syndrome"
Jump to navigation
Jump to search
(Created page with "{| class="wikitable"{| class="wikitable" style="text-align:center; width:100%;" !colspan="4" align="center" style="color:white; font-size:125%; background-color:#31a354"|'''Se...") |
|||
| Line 17: | Line 17: | ||
To be completed | To be completed | ||
=All lines of therapy= | =All lines of therapy= | ||
| − | + | ==Warfarin monotherapy {{#subobject:acc688|Regimen=1}}== | |
| + | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
| + | |- | ||
| + | |[[#top|back to top]] | ||
| + | |} | ||
| + | ===Regimen {{#subobject:3eda79|Variant=1}}=== | ||
| + | {| class="wikitable" style="width: 100%; text-align:center;" | ||
| + | !Study | ||
| + | ![[Levels_of_Evidence#Evidence|Evidence]] | ||
| + | !Comparator | ||
| + | ![[Levels_of_Evidence#Efficacy|Efficacy]] | ||
| + | |- | ||
| + | |[https://www.nejm.org/doi/full/10.1056/NEJMoa035241 Crowther et al. 2003] | ||
| + | | style="background-color:#1a9851" |Phase III (C) | ||
| + | |High-intensity Warfarin (INR 3.1 to 4.0) | ||
| + | | style="background-color:#ffffbf" |Seems not superior | ||
| + | |- | ||
| + | |} | ||
| + | ====Therapy==== | ||
| + | *[[Warfarin (Coumadin)]] PO titrated to goal INR 2.0 to 3.0 | ||
| + | |||
| + | '''Continued indefinitely''' | ||
| + | ===References=== | ||
| + | # Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003 Sep 18;349(12):1133-8. Erratum in: N Engl J Med. 2004 Jul 8;351(2):200. N Engl J Med. 2003 Dec 25;349(26):2577. [https://www.nejm.org/doi/full/10.1056/NEJMoa035241 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/13679527 PubMed] | ||
| + | |||
[[Category:Antiphospholipid antibody syndrome regimens]] | [[Category:Antiphospholipid antibody syndrome regimens]] | ||
Revision as of 02:12, 16 July 2018
| Section editors | |||
|---|---|---|---|
 |
Shruti Chaturvedi, MBBS, MSCI Baltimore, MD |
 |
Benjamin Tillman, MD Nashville, TN |
1 regimens on this page
1 variants on this page
|
Guidelines
To be completed
All lines of therapy
Warfarin monotherapy
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Crowther et al. 2003 | Phase III (C) | High-intensity Warfarin (INR 3.1 to 4.0) | Seems not superior |
Therapy
- Warfarin (Coumadin) PO titrated to goal INR 2.0 to 3.0
Continued indefinitely
References
- Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003 Sep 18;349(12):1133-8. Erratum in: N Engl J Med. 2004 Jul 8;351(2):200. N Engl J Med. 2003 Dec 25;349(26):2577. link to original article PubMed